.Attribute Medicine, Released online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) therapy of individuals along with HER2+ sophisticated breast cancer cells as well as energetic or dependable brain metastases showed constant intracranial activity and wide spread efficiency of T-DXd.